Table 5.

Best overall response among patients receiving parsaclisib monotherapy

Patients	N	ORR, n (% [95% CI])*	CR/CMR, n (%)	PR/PMR, n (%)	SD, n (%)	PD/PMD, n (%)	Not evaluable/not assessed, n (%)
DLBCL†	23	7 (30 [13-53])	4 (17)	3 (13)	4 (17)	11 (48)	1 (4)
GCB	19	6 (32 [13-57])	4 (21)	2 (11)	3 (16)	9 (47)	1 (5)
ABC	2	1 (50 [1-99])	0	1 (50)	0	1 (50)	0
FL	14	10 (71 [42-92])	3 (21)	7 (50)	1 (7)	2 (14)	1 (7)
MZL‡	9	7 (78 [40-97])	3 (33)	4 (44)	1 (11)	1 (11)	0
MCL§	9	6 (67 [30-93])	4 (44)	2 (22)	2 (22)	0	1 (11)
HL‖	10	2 (20 [3-56])	0	2 (20)	3 (30)	4 (40)	1 (10)
CLL§	6	2 (33 [4-78])	0	2 (33)	2 (33)	1 (17)	1 (17)
WM	1	1 (100 [3-100])	0	1 (100)	0	0	0

Assessed by Lugano Classification, International Working Group for CLL Criteria, and the VIth International Workshop on WM by Disease Subtype by CT or PET.

ABC, activated B-cell–like; CMR, complete metabolic response; GCB, germinal center B-cell–like; PD, progressive disease; PMD, progressive metabolic disease; PMR, partial metabolic response; PR, partial response; SD, stable disease.

^*95% CIs were calculated based on the exact method for binomial distributions.

^†Two patients had unknown DLBCL subtype.

^‡Includes extranodal MZL of MALT type (n = 2), nodal MZL (n = 4), splenic MZL (n = 2), and unknown MZL subtype (n = 1).

^§Twelve patients had received ibrutinib before the study, including 4 patients with MCL and 3 patients with CLL, of whom a best overall response of CR or PR was achieved by 2 patients with MCL and 1 patient with CLL.

^‖Includes classic HL (n = 9) and nodular lymphocytic-predominant HL (n = 1).